Wuhan Demeikai Biotechnology Co., Ltd
返回首页 | 加入收藏 | 设为首页
质量是服务的宗旨,24小时客服热线:13260607296
联系方式
Wuhan Demeikai Biotechnology Co., Ltd
whatsapp:+86 18942921723(Ms.Gao) 
+86 13260607296(Mr.Wang)
E-MAIL:wzh@dmksw.xin
Website:http://www.whdksj.com
API Linifanib (ABT-869) Home您现在的位置:HOME >> PRODUCTS >> Inhibitors

API Linifanib (ABT-869)

所属类别:Inhibitors 点击次数:976次 发布时间:2017-04-13

API Linifanib (ABT-869)
详情
 API Linifanib (ABT-869) Basic Info.
MF:C21H18FN5O
MW:375.41
CAS:796967-16-3 
Storage Store at -20°C 
Targets:VEGFR1/FLT1,CSF-1R,VEGFR2/KDR,FLT3,KIT           
 
 
 
ABT-869 Description 
Linifanib (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ with IC50 of 4 nM, 3 nM, 3 nM/4 nM and 66 nM respectively, mostly effective in mutant kinase-dependent cancer cells (i.e. FLT3). Phase 3.
Linifanib shows inhibitory to Kit, PDGFRβ and Flt4 with IC50 of 14 nM, 66 nM and 190 nM in kinases assay. Linifanib also inhibits ligand-induced KDR, PDGFRβ, Kit, and CSF-1R phosphorylation with IC50 of 2 nM, 2 nM, 31 nM and 10 nM at cellular level and this cellular potency could be affected by serum protein. Linifanib suppresses VEGF-stimulated HUAEC proliferation with IC50 of 0.2 nM. While Linifanib has weak activity against tumor cells which are not induced by VEGF or PDGF, except for MV4-11 leukemia cells (with constitutively active form of Flt3) with IC50 of 4 nM. Linifanib could cause a decrease in S and G2-M phases with a corresponding increase in the sub-G0-G1 apoptotic population in MV4-11 cells. Linifanib binds to the ATP-binding site of CSF-1R with Ki of 3 nM.  Linifanib (10 nM) exhibits a reduced phosphorylation of Akt at Ser473 and decreased phosphorylation of GSK3βat Ser9 in Ba/F3 FLT3 ITD cell lines. 
 
 ABT-869 Application
Linifanib (0.3 mg/kg) results in complete inhibition of KDR phosphorylation in lung tissue. Linifanib also inhibits the edema response with ED50 of 0.5 mg/kg. Linifanib (7.5 and 15 mg/kg, bid) significantly inhibits both bFGF- and VEGF-induced angiogenesis in the cornea. Linifanib inhibits tumor growth in flank xenograft models including HT1080, H526, MX-1 and DLD-1 with ED75 from 4.5-12 mg/kg. Linifanib also shows efficacy in A431 and MV4-11 xenografts at low dose levels. Linifanib (12.5 mg/kg bid) reveals a decrease of microvasculure density in MDA-231 xenograft. Linifanib shows a Cmax and AUC24 hours with 0.4 μg/mL and 2.7 μghour/mL in HT1080 fibrosarcoma model.

上一产品: Maytansinol
下一产品: AP26113
友情链接:made-in-china | 西地那非原料药 | 伐地那非原料药 | 他达那非原料药 | 
Copyright © 2004-2015 Wuhan Demechem Bio-tech Co., Ltd All Rights Release all
whatsapp:8618942921723 Company address: wuchang district in wuhan city, hubei province austral soho north 4 1 unit。
收缩
  • QQ咨询

  • SKYPE
  • SKYPE
  • 电话咨询

  • 13260607296